Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af Andecaliximab hos deltagere med Fibrodysplasia Ossificans Progressiva (FOP) (ANDECAL)

3. november 2026 opdateret af: Ashibio Inc

Et fase 2/3, globalt, multicenter, randomiseret, dobbeltblindt, placebokontrolleret, todelt undersøgelse med åben label-udvidelse (OLE) for at vurdere effektiviteten og sikkerheden af ​​Andecaliximab hos deltagere med fibrodysplasia Ossificans Progressiva (FOP)

This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP.

The study is looking at several research questions, including:

  • Safety of andecaliximab in participants with FOP
  • Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO)
  • Whether andecaliximab reduces the number or severity of flare-ups
  • Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s)
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Studieoversigt

Status

Aktiv, ikke rekrutterende

Detaljeret beskrivelse

The ASH-FOP-201 Study consists of 2 parts: Part 1 is a Lead-in Study to assess safety, PK/PD and preliminary efficacy; Part 2 is the Main Study, a Phase 2/3 randomized, double-blind, placebo-controlled trial.

Part 1 is composed of Part 1a, a Na18F positron emission tomography (PET)/computed tomography, less head (CT) Study in up to 6 participants age ≥ 15 years, and Part 1b, a flare-up Study in up to 6 participants ≥ 12 years of age. Participants enrolled in Part 1 will be randomized to one of two dose levels for 13 weeks. Participants in Part 2 will be randomized to one of two dose levels of drug vs. placebo during the 52 week trial. All participants in Part 1 or Part2 will receive study drug in the extension period of the trial.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

92

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • San Francisco, California, Forenede Stater, 94143
        • University of California San Francisco (UCSF)
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • University of Pennsylvania - Perelman Center for Advanced Medicine

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria (Part 1a, 1b, and 2):

  1. Participant and/or guardian able and willing to give informed consent and/or assent as applicable, and willing to adhere to the visits schedule and study procedures.
  2. Clinical diagnosis of FOP including congenital malformation(s) consistent with FOP (e.g., of the great toes), and either episodic soft tissue swelling consistent with an FOP flare-up and/or progressive HO.

4. CAJIS score of ≤19. 5. Disease activity within 1 year of screening visit. Disease activity is defined as physician confirmed flare-up like symptoms or clinical progression including newly identified HO or worsening joint function.

6. Able to understand, undergo, and perform all protocol related procedures, including low-dose WBCT-LH scan without sedation. Assistance from a caregiver is allowed.

7. Agree to provide access to all relevant current and historical medical records (including radiographs or radiographic records) and growth records.

Inclusion Criteria (Part 1a only):

  1. Male or female ≥ 15 years of age.
  2. Serum creatinine ≤ upper limit of normal for age.
  3. No open growth plates on bilateral PA hand/wrist or AP knee films at baseline
  4. Able to receive IV radiotracer [both IV access and no history of a reaction to radiotracer].
  5. No use of bisphosphonates or bone active agent within the past year.
  6. At least 1 active HO lesion at baseline per Na18F PET/CT

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 1b only):

  1. Male or female ≥12 years of age.

  2. History of multiple flare-up episodes within the past 6 months (to be reviewed and confirmed as qualifying by the PI together with the Sponsor). Qualifying flare-up episodes include any of the following:

    • At least 3 qualifying flare-ups in the past 6 months each with continuous symptoms for at least 1 week
    • Migratory flare-up swellings across the back
    • Multiple flare-up episodes the sum of which lasted at least 21 days The timing of the individual flare-ups can be overlapping; they may be ongoing at the time of enrollment or resolved.
  3. The qualifying flare-ups must involve at least 2 of the following flare-up symptoms:

    • Pain
    • Soft tissue swelling
    • Warmth
    • Redness
    • Joint stiffness
    • Decreased range of motion

Additional inclusion criteria apply including those listed above for all parts of the study.

Inclusion Criteria (Part 2 only):

  1. Initial enrollment age requirement is ≥12 years
  2. Enrollment may be extended to participants ≥6 years of age after safety in adult and participants age 12-17 years has been established.
  3. Enrollment of participants ≥2 to <6 years of age will commence after safety in adult and participants ≥6 years of age has been established.

Additional inclusion criteria apply including those listed above for all parts of the study.

Exclusion Criteria:

  1. Body weight <10kg

  2. Known non-healed fracture at time of Study Day 1.

  3. Planned surgery within the timeframe of the study duration or still recovering from recent surgery.

  4. Respiratory compromise that requires use of supplemental oxygen.

  5. Participant has

    • Known monogenic disorder other than FOP.
    • Bone or mineral disorder unrelated to FOP.
  6. Malignancy (within the past 5 years, except non-melanoma skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ [DCIS]).

  7. Known active infection (including fungal, bacterial, mycobacterial, or viral infection including COVID19)

  8. Uncontrolled hypoparathyroidism or hyperparathyroidism.

  9. Per participant report or chart review (no testing required): Uncontrolled hyperthyroidism

  10. Use of the following medication:

    • Systemic corticosteroids with a prednisone equivalent of >10mg/day within 1 week of Study Day 1. If the participant requires chronic use of >10mg/day prednisone equivalent of corticosteroids, eligibility will be discussed with the Sponsor.
    • NSAIDs of higher than doses recommended by the May 2022 ICCFOP guidelines within 1 week of Study Day 1. If the participant requires chronic use of NSAIDs at doses higher than those recommended by the May 2022 ICCFOP guidelines doses, eligibility will be discussed with the Sponsor.
    • Current or chronic use of tetracycline drugs (e.g., tetracycline, demeclocycline, doxycycline, or minocycline).
  11. Chronic use of any of unproven therapies for FOP.

  12. Palovarotene

    • Within 1 month of Study Day 1 for all participants
    • Within 2 years of Study Day 1 for female participants <8 years of age Or male participants <10 years of age
  13. Treatment with another investigational product within 5 half lives of last dose at the time of Study Day 1 or 1 month, whichever is longer.

  14. History of allergy or hypersensitivity to andecaliximab or its excipients.

  15. Significant current laboratory abnormalities

  16. Breastfeeding, pregnant, or planning pregnancy.

  17. Those of childbearing potential unwilling to agree to abstain from sexual activity that could result in pregnancy or unwillingness to use acceptable birth control during the study and for 90 days after the last dose.

  18. Simultaneous participation in another clinical trial involving another investigational product.

  19. Significant medical condition or disability or biochemical or hematologic abnormalities that in the opinion of the Investigator would expose the participant to undue risk, prevent the conduct of study procedures, or confound the study results.

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1a: PET/CT Study

a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) Study to assess the impact of two dose levels of andecaliximab administered subcutaneously (SC), once-a-week (QW) in participants age ≥ 15 years, with FOP on a number of outcomes including Safety, Pharmacokinetic (PK) and pharmacodynamic (PD) and the change from baseline of Na18F uptake in HO lesions by PET/CT scan, and Patient Reported Outcomes (PROs).

Dose level A or B

Dose level A or B (or age adjusted dose)

Eksperimentel: Part 1b: Flare-up Study

a 13-week double-blind (Investigator and Participant blinded; Sponsor unblinded) study to assess the impact of two dose levels of andecaliximab administered SC QW in participants ≥12 years of age with a recent history of frequent flare-up episodes on a number of outcomes including safety, PK/PD, and flare-up incidence and symptoms and PROs.

Dose level A or B

Dose level A or B (or age adjusted dose)

Placebo komparator: Part 2: Main Study

1-year (52-week) double-blind (Investigator, participant, and sponsor all blinded), placebo-controlled study of andecaliximab Dose level A or B (or age adjusted) SC QW or placebo in pediatric and adult patients with FOP. The Main Study will enroll approximately 80 participants, randomized in a 1:1:1 ratio to andecaliximab Dose level A or B (or age adjusted) SC QW or placebo.

Dose level A or B

Dose level A or B (or age adjusted dose)

Blinded

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]
Tidsramme: Week 27 and 53

Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones.

Week 27 and 53

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring i HO-volumen over tid som vurderet af WBCT-LH [Hele kroppen, computertomografi (CT), ikke inklusive hovedet (mindre hoved)]
Tidsramme: Uge 27 og 53
Uge 27 og 53
Antal opblussen som rapporteret af deltageren
Tidsramme: Uge 14, 27 og 53
Uge 14, 27 og 53
Antal opblussen som rapporteret af deltageren og bekræftet af hovedefterforskeren
Tidsramme: Uge 14, 27 og 53
Uge 14, 27 og 53
Percent change from baseline in Na18F standardized uptake value maximum (SUVmax) of up to 7 individual HO lesion(s) per participant active at baseline as assessed by Na18F PET/CT (Part 1a).
Tidsramme: Week 14

SUV max is the SUV of the most intense voxel within a region of interest.

Week 14
Change in HO volume over time as assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)] (Part 1a)
Tidsramme: Week 14

Low dose WBCT-LH (whole body CT less head) is used to create detailed images of soft tissues and bones. In Part 1a, the WBCT-LH scan will be acquired as part of the PET/CT scan at baseline and Week 14.

Week 14
Number of days during which a flare-up is experienced by the participant as reported by the participant
Tidsramme: Week 14, 27 and 53

Flare-up defined as having at least two of the following symptoms: pain, soft tissue swelling, warmth, redness, joint stiffness, or decreased range of motion.

Week 14, 27 and 53
Change in patient joint involvement as assessed by Investigator using Cumulative Analog Joint Involvement Scale (CAJIS)
Tidsramme: Week 27 and 53

CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30.

Week 27 and 53
Change in patient quality of life as assessed by the EuroQol 5 dimensions questionnaire with a 5-level scale (EQ-5D-5L)
Tidsramme: Week 27 and 53

EQ-5D-5L measures: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

Week 27 and 53
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Week 27 and 53

Number of participants with Treatment-Emergent Adverse Events (AE) (TEAEs), i.e., adverse events not present at baseline or exacerbation of a pre-existing condition during the on-treatment period will be reported.

Week 27 and 53
Number of Participants With Serious Treatment-Emergent Adverse Events (Serious TEAEs)
Tidsramme: Week 27 and 53

Number of participants with Serious Treatment-Emergent Adverse Events (AE) (TEAEs), i.e, required initial/prolonged in-patient hospitalization, death, life-threatening, persistent/significant disability/incapacity, congenital anomaly/birth defect, considered as a medically important event.

Week 27 and 53
Number of Participants With TEAEs by Severity
Tidsramme: Week 27 and 53

Severity of TEAEs will be graded as follows: Mild: Does not interfere in a significantly with functioning. Moderate: Causes some impairment of functioning but is not hazardous to health. Severe: Significant impairment or incapacitation; hazardous to one's health. Number of participants with TEAEs by severity will be reported.

Week 27 and 53

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. oktober 2024

Primær færdiggørelse (Anslået)

4. februar 2029

Studieafslutning (Anslået)

4. februar 2029

Datoer for studieregistrering

Først indsendt

17. juni 2024

Først indsendt, der opfyldte QC-kriterier

12. juli 2024

Først opslået (Faktiske)

18. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Redacted Protocol and SAP will be made available.

IPD-delingstidsramme

After completion of the Biologics License Applications (BLA) and all participants have completed the one year extension.

IPD-delingsadgangskriterier

Not decided at this time

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner